New research suggests that people who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional diet and exercise programs.
Research printed in a leading health publication points out that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using these medications must be cognizant of the risk of rapid rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass within about one and a half years.
Weighing Approaches
The study, which reviewed 37 of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
Researchers note that people who shed pounds through dieting generally experience a less rapid creep back—perhaps 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Doctors propose the mode of action of the drugs accounts for the amplified weight return.
These medications imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means appetite is unsuppressed, making binge eating far more likely."
A Chronic Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, given the significant potential of relapse, the treatment is often life-long.
This view is reinforced by drug manufacturers, who state that the results "highlight the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the jabs report a sudden return of appetite.
"It felt as if a switch flipping and you're instantly ravenous," described an individual.
This challenge is exacerbated if users have not adopted sustainable lifestyle or habit changes during therapy.
Widespread Use
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while these medications are effective tools for weight loss, they are not a standalone solution and lasting health benefits hinges on integrated behavioural management.